Novartis Respiratory Drug Suffers Setback - WSJ.com
Links shared publicly online about this topic.
- 1,666total visits
Novartis Respiratory Drug Suffers Setback - WSJ.com
View full resource at online.wsj.com
Tags: Cough, Drug, FDA, Novartis
Most Recently Shared on October 19, 2009 at 11:08 am By:
Novartis eye drug suffers fresh rebuff in Britain | Reuters
reuters.com — “LONDON (Reuters) - Novartis's costly eye drug Lucentis has been rejected for another new use by Britain's health cost-effectiveness watchdog NICE, following a similar setback in July.The National Institute” View full resource at reuters.com
Most Recently Shared on November 24, 2011 at 1:33 pm By:
blogaceutics Pharma and Health Communicator
Novartis eye drug suffers fresh rebuff in Britain [Reuters] http://t.co/Cu5qJG2d
MS drugs get yeas, nays and price increases - FiercePharma
fiercepharma.com — “Lots of news about the multiple sclerosis market today. Two companies raised prices, Novartis received good Gilenya news, while Merck KGaA and Biogen Idec/Acorda Therapeutics suffered setbacks... Read more...” View full resource at fiercepharma.com
Most Recently Shared on January 21, 2011 at 4:22 pm By:
MS drugs get yeas, nays and price increases. http://bit.ly/fUMBvP
Novartis Deal Bolsters Immunogen - Robert Langreth - Treatments - Forbes
blogs.forbes.com — “Immunogen suffered a big setback in August when the FDA refused to even consider approving the new T-DM1 breast cancer drug its partner Roche is testing based on its technology. Immunogen's technology links toxic chemotherapy molecules to precision antibodies that precisely target tumor cells, in hopes of creating kinder, gentler cancer [...]” View full resource at blogs.forbes.com
Most Recently Shared on October 11, 2010 at 5:11 pm By:
Drugs and Devices OW OW Health
Novartis Deal Bolsters Immunogen: Armed Antibodies Aren't Dead Yet http://bit.ly/dsNudZ #drug
Advertisement
